Bone and the Perimenopause

Obstetrics and Gynecology Clinics of North America

Volumn 38, Issue 3, 2011, Pages 503-517

  Lo, Joan C ^a,b   Burnett Bowie, Sherri Ann M ^c,d   Finkelstein, Joel S ^c,d  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone; Fractures; Menopause; Osteoporosis; Perimenopause

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; ESTROGEN; FOLLITROPIN; GESTAGEN; GLUCOCORTICOID; OSTEOCALCIN; PROGESTERONE; RALOXIFENE; VITAMIN D;

AGING; AMENORRHEA; BONE DENSITY; BONE MASS; BONE TURNOVER; CALCIUM INTAKE; CLIMACTERIUM; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; ESTROGEN DEFICIENCY; ETHNIC DIFFERENCE; FEMUR NECK; FOLLITROPIN BLOOD LEVEL; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; LUMBAR SPINE; MENOPAUSAL SYNDROME; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; FEMALE; FRACTURES, BONE; HORMONES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PERIMENOPAUSE;

EID: 80053248920     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2011.07.001     Document Type: Review

References (92)

1. Clinician's Guide to Prevention and Treatment of Osteoporosis 2010, 1-36. National Osteoporosis Foundation, Washington, DC.
2. Neer R.M. Bone loss across the menopausal transition. Ann N Y Acad Sci 2010, 1192:66-71.
3. Finkelstein J.S., Brockwell S.E., Mehta V., et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008, 93:861-868.
4. Lasley B.L., Santoro N., Randolf J.F., et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab 2002, 87:3760-3767.
5. Harlow S.D., Crawford S., Dennerstein L., et al. Recommendations from a multi-study evaluation of proposed criteria for staging reproductive aging. Climacteric 2007, 10:112-119.
6. Ferrell R.J., Sowers M. Longitudinal, epidemiologic studies of female reproductive aging. Ann N Y Acad Sci 2010, 1204:188-197.
7. Randolph J.F., Crawford S., Dennerstein L., et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab 2006, 91:3034-3040.
8. Ahlborg H.G., Johnell O., Nilsson B.E., et al. Bone loss in relation to menopause: a prospective study during 16 years. Bone 2001, 28:327-331.
9. Falch J.A., Sandvik L. Perimenopausal appendicular bone loss: a 10-year prospective study. Bone 1990, 11:425-428.
10. Ravn P., Hetland M.L., Overgaard K., et al. Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy X-ray absorptiometry. J Bone Miner Res 1994, 9:1975-1980.
11. Reeve J., Walton J., Russell L.J., et al. Determinants of the first decade of bone loss after menopause at spine, hip and radius. QJM 1999, 92:261-273.
12. Bainbridge K.E., Sowers M.F., Crutchfield M., et al. Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 2002, 156:410-417.
13. Recker R., Lappe J., Davies K., et al. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000, 15:1965-1973.
14. Recker R.R., Lappe J.M., Davies K.M., et al. Change in bone mass immediately before menopause. J Bone Miner Res 1992, 7:857-862.
15. Sowers M., Crutchfield M., Bandekar R., et al. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res 1998, 13:1134-1140.
16. Slemenda C., Hui S.L., Longcope C., et al. Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 1987, 80:1261-1269.
17. Sowers M.R., Zheng H., Jannausch M.L., et al. Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. J Clin Endocrinol Metab 2010, 95:2155-2162.
18. Guthrie J.R., Ebeling P.R., Hopper J.L., et al. A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int 1998, 8:282-290.
19. Pouilles J.M., Tremollieres F., Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int 1993, 52:340-343.
20. Rannevik G., Jeppsson S., Johnell O., et al. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995, 21:103-113.
21. Cummings S.R., Browner W.S., Bauer D., et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998, 339:733-738.
22. Greendale G.A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997, 12:1833-1843.
23. Filicori M., Santoro N., Merriam G.R., et al. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 1986, 62:1136-1144.
24. Santoro N., Brown J.R., Adel T., et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996, 81:1495-1501.
25. Ebeling P.R., Atley L.M., Guthrie J.R., et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996, 81:3366-3371.
26. Guthrie J.R., Lehert P., Dennerstein L., et al. The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study. Osteoporos Int 2004, 15:881-886.
27. Ahlborg H.G., Johnell O., Turner C.H., et al. Bone loss and bone size after menopause. N Engl J Med 2003, 349:327-334.
28. Sowers M.R., Finkelstein J.S., Ettinger B., et al. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 2003, 14:44-52.
29. Sowers M.R., Jannausch M., McConnell D., et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab 2006, 91:1261-1267.
30. Khosla S., Melton L.J., Riggs B.L. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res 2011, 26:441-451.
31. Iqbal J., Sun L., Kumar T.R., et al. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006, 103:14925-14930.
32. Sun L., Peng Y., Sharrow A.C., et al. FSH directly regulates bone mass. Cell 2006, 125:247-260.
33. Abel M.H., Huhtaniemi I., Pakarinen P., et al. Age-related uterine and ovarian hypertrophy in FSH receptor knockout and FSHbeta subunit knockout mice. Reproduction 2003, 125:165-173.
34. Nicks K.M., Fowler T.W., Akel N.S., et al. Bone turnover across the menopause transition: The role of gonadal inhibins. Ann N Y Acad Sci 2010, 1192:153-160.
35. Santoro N., Crawford S.L., Lasley W.L., et al. Factors related to declining luteal function in women during the menopausal transition. J Clin Endocrinol Metab 2008, 93:1711-1721.
36. Seifert-Klauss V., Prior J.C. Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010, 2010:845180.
37. Grewal J., Sowers M.R., Randolph J.F., et al. Low bone mineral density in the early menopausal transition: role for ovulatory function. J Clin Endocrinol Metab 2006, 91:3780-3785.
38. Vasikaran S., Eastell R., Bruyere O., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
39. Akesson K., Ljunghall S., Jonsson B., et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995, 10:1823-1829.
40. Delmas P.D., Eastell R., Garnero P., et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl 6):S2-S17.
41. Garnero P., Hausherr E., Chapuy M.C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996, 11:1531-1538.
42. Garnero P., Shih W.J., Gineyts E., et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994, 79:1693-1700.
43. Bauer D.C., Sklarin P.M., Stone K.L., et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999, 14:1404-1410.
44. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000, 11(Suppl 6):S55-S65.
45. Melton L.J., Crowson C.S., O'Fallon W.M., et al. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003, 18:312-318.
46. Hansen M.A., Overgaard K., Riis B.J., et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991, 303:961-964.
47. Rosen C.J., Chesnut C.H., Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997, 82:1904-1910.
48. Riis B.J., Hansen M.A., Jensen A.M., et al. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996, 19:9-12.
49. Sowers M.R., Greendale G.A., Bondarenko I., et al. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 2003, 14:191-197.
50. Finkelstein J.S., Sowers M., Greendale G.A., et al. Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab 2002, 87:3051-3056.
51. Hassager C., Colwell A., Assiri A.M., et al. Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol (Oxf) 1992, 37:45-50.
52. Nordin B.E., Clifton P.M., et al. A longitudinal study of bone-related biochemical changes at the menopause. Clin Endocrinol (Oxf) 2004, 61:123-130. JM WI.
53. Ito M., Lang T.F., Jergas M., et al. Spinal trabecular bone loss and fracture in American and Japanese women. Calcif Tissue Int 1997, 61:123-128.
54. Finkelstein J.S., Lee M.L., Sowers M., et al. Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab 2002, 87:3057-3067.
55. Holmberg A.H., Johnell O., Nilsson P.M., et al. Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. Osteoporos Int 2006, 17:1065-1077.
56. Huopio J., Kroger H., Honkanen R., et al. Risk factors for perimenopausal fractures: a prospective study. Osteoporos Int 2000, 11:219-227.
57. Torgerson D.J., Campbell M.K., Thomas R.E., et al. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996, 11:293-297.
58. Khalil N., Sutton-Tyrrell K., Strotmeyer E.S., et al. Menopausal bone changes and incident fractures in diabetic women: a cohort study. Osteoporos Int 2011, 22:1367-1376.
59. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17:25-54.
60. Ensrud K.E., Ewing S.K., Stone K.L., et al. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc 2003, 51:1740-1747.
61. Avenell A., Gillespie W.J., Gillespie L.D., et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009, 2. CD000227.
62. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.
63. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637-1642.
64. Dawson-Hughes B., Harris S.S., Krall E.A., et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
65. Grant A.M., Avenell A., Campbell M.K., et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005, 365:1621-1628.
66. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
67. Finkelstein J.S. Calcium plus vitamin D for postmenopausal women-bone appetit?. N Engl J Med 2006, 354:750-752.
68. Citron J.T., Ettinger B., Genant H.K. Spinal bone mineral loss in estrogen-replete, calcium-replete premenopausal women. Osteoporos Int 1995, 5:228-233.
69. Dawson-Hughes B., Dallal G.E., Krall E.A., et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990, 323:878-883.
70. Reid I.R., Mason B., Horne A., et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006, 119:777-785.
71. Dietary reference intakes for calcium and vitamin D 2011, Institute of Medicine of the National Academies, Washington, DC.
72. Bolland M.J., Avenell A., Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
73. Bolland M.J., Barber P.A., Doughty R.N., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336:262-266.
74. Bailey R.L., Dodd K.W., Goldman J.A., et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010, 140:817-822.
75. Chapuy M.C., Schott A.M., Garnero P., et al. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab 1996, 81:1129-1133.
76. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
77. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009, 339:b3692.
78. Holick M.F., MacLaughlin J.A., Clark M.B., et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980, 210:203-205.
79. Norman A.W. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr 1998, 67:1108-1110.
80. Wortsman J., Matsuoka L.Y., Chen T.C., et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000, 72:690-693.
81. Kanis J.A., McCloskey E.V., Johansson H., et al. A reference standard for the description of osteoporosis. Bone 2008, 42:467-475.
82. Baim S., Binkley N., Bilezikian J.P., et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008, 11:75-91.
83. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011, 154:356-364.
84. Waugh E.J., Lam M.A., Hawker G.A., et al. Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature. Osteoporos Int 2009, 20:1-21.
85. Tremollieres F., Cochet T., Cohade C., et al. Fracture risk in early postmenopausal women assessed using FRAX. Joint Bone Spine 2010, 77:345-348.
86. Ettinger B., Black D.M., Dawson-Hughes B., et al. Updated fracture incidence rates for the US version of FRAX. Osteoporos Int 2010, 21:25-33.
87. Tremollieres F.A., Pouilles J.M., Drewniak N., et al. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 2010, 25:1002-1009.
88. Tosteson A.N., Melton L.J., Dawson-Hughes B., et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19:437-447.
89. Eng-Wong J., Reynolds J.C., Venzon D., et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006, 91:3941-3946.
90. Cauley J.A., Seeley D.G., Ensrud K., et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995, 122:9-16.
91. Cauley J.A., Zmuda J.M., Ensrud K.E., et al. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001, 86:5700-5705.
92. Schneider D.L., Barrett-Connor E.L., Morton D.J. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997, 277:543-547.